Learn more →
Back to Expert Scholars
targeted-therapy / targeted-therapyHead and Neck Cancer

Makoto Tahara

田原信

MD, PhD

🏢National Cancer Center Hospital East, Chiba(日本国立癌症研究中心东院)🌐Japan

Chief, Department of Head and Neck Medical Oncology头颈部肿瘤内科主任

48
h-index
2
Key Papers
4
Awards
2
Key Contributions

👥Biography 个人简介

Makoto Tahara is Japan's leading head and neck cancer medical oncologist, directing the program at NCC Hospital East and conducting pivotal Asian trials for HNSCC and thyroid cancer. He led key studies on lenvatinib in head and neck cancer and thyroid malignancies, and represents Asia-Pacific perspectives in global HNSCC guideline development.

Share:

🧪Research Fields 研究领域

Head and Neck Cancer头颈部癌症
Lenvatinib仑伐替尼
Asian Clinical Trials亚洲临床试验
Thyroid Cancer甲状腺癌
Immunotherapy免疫治疗

🎓Key Contributions 主要贡献

Lenvatinib in Head and Neck and Thyroid Cancers

Led multiple Asian and global trials of lenvatinib in radioiodine-refractory differentiated thyroid cancer and recurrent/metastatic HNSCC, establishing lenvatinib as a standard treatment option and elucidating predictors of response.

Asia-Pacific HNSCC Clinical Trial Leadership

Initiated and led Japanese and pan-Asian clinical trials for HNSCC immunotherapy and targeted therapy, incorporating Asian-specific epidemiology including higher proportions of hypopharyngeal and oral cavity cancers into trial design.

Representative Works 代表性著作

[1]

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer (SELECT)

New England Journal of Medicine (2015)

Pivotal phase III SELECT trial demonstrating unprecedented progression-free survival improvement with lenvatinib in radioiodine-refractory differentiated thyroid cancer, gaining global regulatory approval.

[2]

Phase II study of lenvatinib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Annals of Oncology (2022)

Demonstrated promising antitumor activity of lenvatinib monotherapy in platinum-pretreated R/M HNSCC, supporting further investigation of multi-kinase inhibition in this setting.

🏆Awards & Recognition 奖项与荣誉

🏆Japan Society of Clinical Oncology (JSCO) Award for Excellence
🏆NCC Japan Outstanding Researcher Award
🏆AACR-JCA Cancer Research Exchange Prize
🏆Asia-Pacific Journal of Clinical Oncology Distinguished Investigator

📄Data Sources 数据来源

Last updated: 2026-01-15 | All information from publicly available academic sources

关注 田原信 的研究动态

Follow Makoto Tahara's research updates

留下邮箱,当我们发布与 Makoto Tahara(National Cancer Center Hospital East, Chiba)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment